H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Polymyositis pipeline constitutes 7+ key companies continuously working towards developing 7+ Polymyositis treatment ...

SAN FRANCISCO--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic ...

The idiopathic inflammatory myositis treatment market is poised for significant expansion, driven by the introduction of innovative targeted therapies and increasing disease awareness. Key idiopathic ...

Idiopathic inflammatory myopathies, known collectively as myositis, are chronic diseases that cause disability, mainly from muscle weakness, despite the use of immunosuppressive therapies. An improved ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Although new targets and therapies are on the horizon, current myositis treatment strategies rely ...

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for ...

Please provide your email address to receive an email when new articles are posted on . Among systemic rheumatic diseases, the risk for opportunistic infection is highest among patients with ...

Cartesian Therapeutics (RNAC) is maintained at a "Buy" rating, driven by progress in its Descartes-08 mRNA CAR-T pipeline for autoimmune disorders. RNAC's phase 3 AURORA study targets AChR Ab+ ...

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic ...